Filing Flows › AstraZeneca (AZN) › Oncology revenue
AstraZeneca (AZN) Oncology revenue by quarter
AstraZeneca's Oncology revenue was $7.1B in Q3 2026 (third quarter 2026), +15% from Q3 2025. Over the last 3 quarters it ranged from $5.6B (Q1 2025) to $7.1B (Q3 2026).
| Quarter | Oncology revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $7.1B | +15% | +15% |
| Q3 2025 | $6.1B | +9% | — |
| Q1 2025 | $5.6B | — | — |
Q3 2026 at a glance
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is AstraZeneca's Oncology revenue?
AstraZeneca's Oncology revenue was $7.1B in Q3 2026 (third quarter 2026), +15% from Q3 2025.
How has AstraZeneca's Oncology revenue changed?
Over the last 3 quarters it ranged from $5.6B (Q1 2025) to $7.1B (Q3 2026).